Incyte CFO Christiana Stamoulis to Depart, Search for Successor Begins

Incyte Corporation's CFO, Christiana Stamoulis, is stepping down to pursue another opportunity. Her departure is effective September 16, 2025, and the company has begun searching for a successor. Stamoulis will remain with Incyte to ensure a smooth transition. The leadership change may impact the company's strategic direction and financial performance.

Biopharmaceutical company Incyte Corporation (NASDAQ: INCY) announced that Executive Vice President and Chief Financial Officer Christiana Stamoulis will leave the company effective September 16, 2025. Stamoulis, who joined Incyte in 2019, will remain with the company until her departure date to facilitate a smooth transition [1].

Incyte, headquartered in Wilmington, Delaware, focuses on developing and commercializing therapeutics for patients with unmet medical needs, with a portfolio concentrated in oncology and inflammation and autoimmunity treatments [1]. Despite the leadership change, the company reaffirmed its financial guidance for 2025 as disclosed during its second-quarter earnings announcement on July 29. The company stated that its financial position and strategic direction remain unchanged [1].

The announcement comes as part of a press release statement that included standard forward-looking statements and disclaimers regarding the company’s operations and financial outlook [1]. In other recent news, Incyte reported a strong second-quarter performance for 2025, with earnings surpassing consensus expectations. Jakafi sales were particularly notable, reaching $764 million, exceeding the anticipated $743 million. Niktimvo also showed impressive growth, generating $36 million in revenue, marking a 166% increase quarter-over-quarter [1].

The leadership change may impact the company's strategic direction and financial performance. Analysts have responded to the news with varying reactions. TD Cowen raised its price target for Incyte to $89, maintaining a Buy rating due to the robust performance across all product lines. Truist Securities also increased its price target to $79, noting the strong sales figures for Jakafi. Barclays initiated coverage on Incyte with an Overweight rating, highlighting the company’s potential for revenue growth in the coming years. RBC Capital raised its price target to $72, driven by demand for Incyte’s products, including Jakafi and Niktimvo. BMO Capital adjusted its price target to $60, expressing cautious optimism about the company’s future under new leadership [1].

Incyte has begun the search for Stamoulis' successor, and the company remains focused on its strategic goals and financial performance. The company's strong second-quarter results and positive analyst reactions suggest that Incyte is well-positioned to navigate the leadership transition and maintain its momentum.

References:
[1] https://www.investing.com/news/company-news/incyte-cfo-christiana-stamoulis-to-step-down-in-september-93CH-4171224
[2] https://seekingalpha.com/news/4479125-incyte-cfo-to-step-down-in-september-2025